Further studies deciphering the mechanism of the combined effects supported the hypothesis that MCL‐1 downregulation via CDK9 inhibition can sensitize MCL cells to BCL‐2 inhibition. This evidence concerns the gene CDK9 and mantle cell lymphoma.